{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2010"],"condition":["unresectable metastatic colorectal cancer"],"disease":["Unresectable Metastatic Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2620026"],"location":["Japan"],"study_start_month":["11"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Phase 1/2 study of cetuximab plus capecitabine in elderly patients with kras-wild type mCRC who have no prior chemotherapy","description":"Interventions: capecitabine,cetuximab\nPrimary outcome(s): Safety/efficacy\nStudy Design: Single arm Non-randomized","dates":{"creation":"2010-11-15"},"accession":"2620026","cross_references":{"Japan Primary Registries Network":["JPRN-UMIN000004579"]}}